AAPL338.19-1.89 (-0.56%) ▼|ABBV263.30+0.10 (+0.04%) ▲|ABT108.00+0.73 (+0.68%) ▲|ACN173.17+8.51 (+5.17%) ▲|ADBE263.43+14.25 (+5.72%) ▲|AMAT436.45-40.01 (-8.40%) ▼|AMD429.56-25.06 (-5.51%) ▼|AMGN387.64-5.46 (-1.39%) ▼|AMT179.26+7.76 (+4.52%) ▲|AMZN226.65-4.21 (-1.82%) ▼|AVGO370.32-10.59 (-2.78%) ▼|AXP331.50-5.13 (-1.52%) ▼|BA214.01-7.55 (-3.41%) ▼|BAC61.07-1.55 (-2.48%) ▼|BKNG201.30+1.99 (+1.00%) ▲|BLK1,079.19-18.36 (-1.67%) ▼|BMY63.10-0.50 (-0.79%) ▼|BNY152.50-3.99 (-2.55%) ▼|BRK-B509.16-3.21 (-0.63%) ▼|C127.13-5.34 (-4.03%) ▼|CAT782.71-58.14 (-6.91%) ▼|CL93.49+0.76 (+0.82%) ▲|CMCSA24.61+0.42 (+1.74%) ▲|COF208.71-3.70 (-1.74%) ▼|COP118.06+3.96 (+3.47%) ▲|COST974.03+7.45 (+0.77%) ▲|CRM188.38+6.88 (+3.79%) ▲|CSCO112.48-3.10 (-2.68%) ▼|CVS105.92-3.42 (-3.13%) ▼|CVX191.86+4.28 (+2.28%) ▲|DE610.95-28.89 (-4.52%) ▼|DHR196.49-2.56 (-1.29%) ▼|DIS98.48-0.41 (-0.41%) ▼|DUK129.08-0.16 (-0.12%) ▼|EMR145.73-6.08 (-4.01%) ▼|FDX308.61-4.03 (-1.29%) ▼|GD380.96-12.23 (-3.11%) ▼|GE350.63-12.96 (-3.56%) ▼|GEV900.28-43.10 (-4.57%) ▼|GILD132.73-1.59 (-1.18%) ▼|GM89.40-0.90 (-1.00%) ▼|GOOG335.76+3.16 (+0.95%) ▲|GOOGL336.71+3.00 (+0.90%) ▲|GS980.75-52.59 (-5.09%) ▼|HD338.27-6.20 (-1.80%) ▼|HON241.12-5.93 (-2.40%) ▼|IBM226.44-1.11 (-0.49%) ▼|INTC81.88-4.42 (-5.12%) ▼|INTU333.13+20.14 (+6.43%) ▲|ISRG353.10-8.70 (-2.40%) ▼|JNJ265.53-1.20 (-0.45%) ▼|JPM344.71-12.60 (-3.53%) ▼|KO89.08+0.81 (+0.92%) ▲|LIN511.17-0.01 (0.00%) ▼|LLY1,210.02-10.64 (-0.87%) ▼|LMT569.20-12.11 (-2.08%) ▼|LOW215.68-2.56 (-1.17%) ▼|LRCX252.35-17.26 (-6.40%) ▼|MA563.32+0.57 (+0.10%) ▲|MCD271.52-1.50 (-0.55%) ▼|MDLZ64.99+2.51 (+4.02%) ▲|MDT87.54+0.66 (+0.76%) ▲|META585.61-7.80 (-1.31%) ▼|MMM177.95-4.53 (-2.48%) ▼|MO74.92+0.10 (+0.13%) ▲|MRK130.36-1.46 (-1.11%) ▼|MS203.13-8.45 (-3.99%) ▼|MSFT390.54-2.81 (-0.71%) ▼|MU739.00-81.53 (-9.94%) ▼|NEE88.46-0.82 (-0.92%) ▼|NFLX73.63+1.24 (+1.71%) ▲|NKE43.22+0.17 (+0.39%) ▲|NOW115.76+5.14 (+4.65%) ▲|NVDA190.01-7.00 (-3.55%) ▼|ORCL117.74-2.22 (-1.85%) ▼|PEP143.50+0.64 (+0.45%) ▲|PFE25.15-0.10 (-0.40%) ▼|PG146.10-2.78 (-1.87%) ▼|PLTR123.00-0.53 (-0.43%) ▼|PM198.44-1.73 (-0.86%) ▼|QCOM155.68-7.20 (-4.42%) ▼|RTX215.25-3.33 (-1.52%) ▼|SBUX104.14+1.04 (+1.01%) ▲|SCHW104.47-1.50 (-1.42%) ▼|SO96.05-0.73 (-0.75%) ▼|SPG235.61-1.09 (-0.46%) ▼|T23.94-0.72 (-2.92%) ▼|TMO576.46+0.05 (+0.01%) ▲|TMUS181.52-0.87 (-0.48%) ▼|TSLA298.32-9.12 (-2.97%) ▼|TXN271.30-5.77 (-2.08%) ▼|UBER71.20+0.46 (+0.65%) ▲|UNH420.57-8.22 (-1.92%) ▼|UNP292.19-2.26 (-0.77%) ▼|UPS104.56-0.97 (-0.92%) ▼|USB62.82-1.61 (-2.50%) ▼|V368.73+2.14 (+0.58%) ▲|VZ47.22-0.97 (-2.01%) ▼|WFC83.87-3.00 (-3.45%) ▼|WMT114.22+1.12 (+0.99%) ▲|XOM156.75+3.71 (+2.42%) ▲|AAPL338.19-1.89 (-0.56%) ▼|ABBV263.30+0.10 (+0.04%) ▲|ABT108.00+0.73 (+0.68%) ▲|ACN173.17+8.51 (+5.17%) ▲|ADBE263.43+14.25 (+5.72%) ▲|AMAT436.45-40.01 (-8.40%) ▼|AMD429.56-25.06 (-5.51%) ▼|AMGN387.64-5.46 (-1.39%) ▼|AMT179.26+7.76 (+4.52%) ▲|AMZN226.65-4.21 (-1.82%) ▼|AVGO370.32-10.59 (-2.78%) ▼|AXP331.50-5.13 (-1.52%) ▼|BA214.01-7.55 (-3.41%) ▼|BAC61.07-1.55 (-2.48%) ▼|BKNG201.30+1.99 (+1.00%) ▲|BLK1,079.19-18.36 (-1.67%) ▼|BMY63.10-0.50 (-0.79%) ▼|BNY152.50-3.99 (-2.55%) ▼|BRK-B509.16-3.21 (-0.63%) ▼|C127.13-5.34 (-4.03%) ▼|CAT782.71-58.14 (-6.91%) ▼|CL93.49+0.76 (+0.82%) ▲|CMCSA24.61+0.42 (+1.74%) ▲|COF208.71-3.70 (-1.74%) ▼|COP118.06+3.96 (+3.47%) ▲|COST974.03+7.45 (+0.77%) ▲|CRM188.38+6.88 (+3.79%) ▲|CSCO112.48-3.10 (-2.68%) ▼|CVS105.92-3.42 (-3.13%) ▼|CVX191.86+4.28 (+2.28%) ▲|DE610.95-28.89 (-4.52%) ▼|DHR196.49-2.56 (-1.29%) ▼|DIS98.48-0.41 (-0.41%) ▼|DUK129.08-0.16 (-0.12%) ▼|EMR145.73-6.08 (-4.01%) ▼|FDX308.61-4.03 (-1.29%) ▼|GD380.96-12.23 (-3.11%) ▼|GE350.63-12.96 (-3.56%) ▼|GEV900.28-43.10 (-4.57%) ▼|GILD132.73-1.59 (-1.18%) ▼|GM89.40-0.90 (-1.00%) ▼|GOOG335.76+3.16 (+0.95%) ▲|GOOGL336.71+3.00 (+0.90%) ▲|GS980.75-52.59 (-5.09%) ▼|HD338.27-6.20 (-1.80%) ▼|HON241.12-5.93 (-2.40%) ▼|IBM226.44-1.11 (-0.49%) ▼|INTC81.88-4.42 (-5.12%) ▼|INTU333.13+20.14 (+6.43%) ▲|ISRG353.10-8.70 (-2.40%) ▼|JNJ265.53-1.20 (-0.45%) ▼|JPM344.71-12.60 (-3.53%) ▼|KO89.08+0.81 (+0.92%) ▲|LIN511.17-0.01 (0.00%) ▼|LLY1,210.02-10.64 (-0.87%) ▼|LMT569.20-12.11 (-2.08%) ▼|LOW215.68-2.56 (-1.17%) ▼|LRCX252.35-17.26 (-6.40%) ▼|MA563.32+0.57 (+0.10%) ▲|MCD271.52-1.50 (-0.55%) ▼|MDLZ64.99+2.51 (+4.02%) ▲|MDT87.54+0.66 (+0.76%) ▲|META585.61-7.80 (-1.31%) ▼|MMM177.95-4.53 (-2.48%) ▼|MO74.92+0.10 (+0.13%) ▲|MRK130.36-1.46 (-1.11%) ▼|MS203.13-8.45 (-3.99%) ▼|MSFT390.54-2.81 (-0.71%) ▼|MU739.00-81.53 (-9.94%) ▼|NEE88.46-0.82 (-0.92%) ▼|NFLX73.63+1.24 (+1.71%) ▲|NKE43.22+0.17 (+0.39%) ▲|NOW115.76+5.14 (+4.65%) ▲|NVDA190.01-7.00 (-3.55%) ▼|ORCL117.74-2.22 (-1.85%) ▼|PEP143.50+0.64 (+0.45%) ▲|PFE25.15-0.10 (-0.40%) ▼|PG146.10-2.78 (-1.87%) ▼|PLTR123.00-0.53 (-0.43%) ▼|PM198.44-1.73 (-0.86%) ▼|QCOM155.68-7.20 (-4.42%) ▼|RTX215.25-3.33 (-1.52%) ▼|SBUX104.14+1.04 (+1.01%) ▲|SCHW104.47-1.50 (-1.42%) ▼|SO96.05-0.73 (-0.75%) ▼|SPG235.61-1.09 (-0.46%) ▼|T23.94-0.72 (-2.92%) ▼|TMO576.46+0.05 (+0.01%) ▲|TMUS181.52-0.87 (-0.48%) ▼|TSLA298.32-9.12 (-2.97%) ▼|TXN271.30-5.77 (-2.08%) ▼|UBER71.20+0.46 (+0.65%) ▲|UNH420.57-8.22 (-1.92%) ▼|UNP292.19-2.26 (-0.77%) ▼|UPS104.56-0.97 (-0.92%) ▼|USB62.82-1.61 (-2.50%) ▼|V368.73+2.14 (+0.58%) ▲|VZ47.22-0.97 (-2.01%) ▼|WFC83.87-3.00 (-3.45%) ▼|WMT114.22+1.12 (+0.99%) ▲|XOM156.75+3.71 (+2.42%) ▲|
25.9 C
New York
Thursday, July 30, 2026

Tag: Paris:ALCLS

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

Résultats de l’Assemblée Générale Mixte de Cellectis du 25 juin 2026

NEW YORK, 25 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome pour développer des thérapies cellulaires et géniques, a tenu son assemblée générale mixte ce jour à 14h30, heure de Paris, à l’auditorium du site Biopark, situé au 11 rue Watt, 4ème étage, 75013 Paris, France.

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

Monthly information on share capital and company voting rights

PARIS, July 04, 2025 (GLOBE NEWSWIRE) --

(Article 223-16 of General Regulation of the French financial markets authority)

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

PARIS, 04 juill. 2025 (GLOBE NEWSWIRE) --

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)
(Article 223-16 of General Regulation of the French financial markets authority)

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsParis:ALCLS